Review



maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative
    Maleimidocaproyl Mc Glycylglycylphenylalanylglycylexatecan Derivative, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/MC-GGFG-Exatecan/pm42236121-57-0-53
    Average 94 stars, based on 7 article reviews
    maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Generated:

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
    Article Snippet: The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 .. The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 ..

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
    Article Snippet: .. The DS-7300a ADC was generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described. m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described. ..

    Sequencing:

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
    Article Snippet: The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 .. The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 ..

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
    Article Snippet: .. The DS-7300a ADC was generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described. m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described. ..

    Derivative Assay:

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
    Article Snippet: The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 .. The DS-7300a ADCwas generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described.20 m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described.67 ..

    Article Title: Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability
    Article Snippet: .. The DS-7300a ADC was generated by producing and purifying the B7-H3 humanized M30 antibody [Sequence 85 (HC) and 77 (LC) derived from US patent 9,371,395 B2] and randomly conjugating it to the exatecan derivative-based cytotoxic payload DXd (MedChemExpress, cat # HY-13631D) on endogenous cysteines via a cleavable tetrapeptide to create an average DAR of 4 as previously described. m276-Tesirine was generated by randomly conjugating the m276 parent antibody to the drug-linker Tesirine (MedChemExpress) to obtain an average DAR of 2 as previously described. ..

    other:

    Article Title: Humanized antibodies against Nectin-2 and drug conjugates thereof
    Article Snippet: DXd—an exatecan derivative, a potent DNA topoisomerase I inhibitor (For example Cat. No.: HY-13631D of MCE®).



    Similar Products

    maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative  (MedChemExpress)
    94
    MedChemExpress maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative
    Maleimidocaproyl Mc Glycylglycylphenylalanylglycylexatecan Derivative, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/MC-GGFG-Exatecan/pm42236121-57-0-53
    Average 94 stars, based on 1 article reviews
    maleimidocaproyl mc glycylglycylphenylalanylglycylexatecan derivative - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    exatecan derivative  (MedChemExpress)
    94
    MedChemExpress exatecan derivative
    Exatecan Derivative, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/Exatecan/us12612457-250-1-15
    Average 94 stars, based on 1 article reviews
    exatecan derivative - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    exatecan derived adc  (Daiichi Sankyo)
    86
    Daiichi Sankyo exatecan derived adc
    Exatecan Derived Adc, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/deruxtecan+trastuzumab/pmc12897389-33-11-4
    Average 86 stars, based on 1 article reviews
    exatecan derived adc - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dx 8951 dxd derivative  (MedChemExpress)
    94
    MedChemExpress dx 8951 dxd derivative
    Dx 8951 Dxd Derivative, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/Dxd/pm38254706-73-6-17
    Average 94 stars, based on 1 article reviews
    dx 8951 dxd derivative - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    glycolic acid derivative of exatecan dxd  (Daiichi Sankyo)
    90
    Daiichi Sankyo glycolic acid derivative of exatecan dxd
    Glycolic Acid Derivative Of Exatecan Dxd, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/glycolic+acid+derivative+of+exatecan+dxd/pm36650546-97-19-5
    Average 90 stars, based on 1 article reviews
    glycolic acid derivative of exatecan dxd - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    camptothecin analog exatecan (dxd; dx-8951 derivative  (Daiichi Sankyo)
    90
    Daiichi Sankyo camptothecin analog exatecan (dxd; dx-8951 derivative
    Characteristics of clinical studies.
    Camptothecin Analog Exatecan (Dxd; Dx 8951 Derivative, supplied by Daiichi Sankyo, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/exatecan+derivative/camptothecin+analog+exatecan++dxd++dx+8951+derivative/pmc08269333-35-7-58
    Average 90 stars, based on 1 article reviews
    camptothecin analog exatecan (dxd; dx-8951 derivative - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Characteristics of clinical studies.

    Journal: Cancers

    Article Title: Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

    doi: 10.3390/cancers13133126

    Figure Lengend Snippet: Characteristics of clinical studies.

    Article Snippet: Trastuzumab deruxtecan (DS-8201A, T-Dxd) , HER2 , Camptothecin analog exatecan (DXd; DX-8951 derivative) , Cleavable tetrapeptide linker, Gly-Phe-Leu-Gly (GFLG) , Biliary tract cancer, breast cancer, colorectal cancer, endometrial cancer, lung cancer, salivary glands cancer , I , 60/8 , ECOG: 0–1 , Safety (TEAE), tolerability , In vivo efficacy (CR, DCR, ORR PD, PFS, PR, SD, TTR) , Daiichi Sankyo Inc. , Tsurutani 2020 [ ] , NCT03248492— http://adc.expert/2eYaukS (accessed on May, 16th 2021) NCT03734029— https://clinicaltrials.gov/ct2/show/NCT03734029 (accessed on May 16th, 2021) NCT03523585— https://clinicaltrials.gov/ct2/show/NCT03523585 (accessed on May 16th, 2021) NCT03529110— https://clinicaltrials.gov/ct2/show/NCT03529110 (accessed onMay 16th, 2021).

    Techniques: In Vivo

    Summarizes the design, approved indications and developer of ADCs approved by the FDA.

    Journal: Cancers

    Article Title: Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

    doi: 10.3390/cancers13133126

    Figure Lengend Snippet: Summarizes the design, approved indications and developer of ADCs approved by the FDA.

    Article Snippet: Trastuzumab deruxtecan (DS-8201A, T-Dxd) , HER2 , Camptothecin analog exatecan (DXd; DX-8951 derivative) , Cleavable tetrapeptide linker, Gly-Phe-Leu-Gly (GFLG) , Biliary tract cancer, breast cancer, colorectal cancer, endometrial cancer, lung cancer, salivary glands cancer , I , 60/8 , ECOG: 0–1 , Safety (TEAE), tolerability , In vivo efficacy (CR, DCR, ORR PD, PFS, PR, SD, TTR) , Daiichi Sankyo Inc. , Tsurutani 2020 [ ] , NCT03248492— http://adc.expert/2eYaukS (accessed on May, 16th 2021) NCT03734029— https://clinicaltrials.gov/ct2/show/NCT03734029 (accessed on May 16th, 2021) NCT03523585— https://clinicaltrials.gov/ct2/show/NCT03523585 (accessed on May 16th, 2021) NCT03529110— https://clinicaltrials.gov/ct2/show/NCT03529110 (accessed onMay 16th, 2021).

    Techniques: